Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure.
For short term treatment of acutely decompensated severe chronic heart failure (CHF). Also being investigated for use/treatment in heart disease.
Cardiology Department, Sahlgrenska University Hospital, Gothenburg, Sweden
Emory University Hospital, Atlanta, Georgia, United States
Kuopio University Hospital, Kuopio, Finland
Helsinki University Central Hospital, Helsinki, Finland
Helsinki University Central Hospital, Helsinki, Finland
Turku University Central Hospital, Turku, Finland
Intensive Care Unit, Nepean Hospital, Penrith, New South Wales, Australia
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
VA Greater Los Angeles Healthcare System, Los Angeles, California, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.